Lloyd A Rowland
CIK 1236395 · General Counsel · last filed 2025-03-20
Lloyd A Rowland is a General Counsel who has filed 51 SEC Form 4 insider transactions across 3 companies since 2007. The most recent filing shows the insider sold $6.1K of CTMX on Mar 20, 2025. Across all open-market trades the lifetime net is −$1.3M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $299.2K across reported positions. 6 SEC filings were submitted jointly with Xencor Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AMLN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
9360 TOWNE CENTRE DR
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CTMX | General Counsel | 120,594 | $2.06 | $248.4K | $46.0K | 19 | 2025-03-20 |
| XNCR | Sr. V.P. and General Counsel | 1,501 | $33.85 | $50.8K | $0 | 5 | 2016-01-28 |
| AMYLIN PHARMACEUTICALS INC (AMLN) Delisted | VP, Chief Compliance Officer | 47,065 | — | — | -$1.33M | 26 | 2012-07-26 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| AMLN | Direct | 35,426 | 75.3% | 2012-07-26 |
| by ESOP | 7,974 | 16.9% | 2012-07-26 | |
| Indirect-401k | 3,665 | 7.8% | 2012-07-26 | |
| Total | 47,065 |
Recent Filings
51 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-20 | CTMX | Sell (S) | −10,203 | -$6.1K | EDGAR |
| 2024-08-22 | CTMX | Mixed | +7,069 | -$5.1K | EDGAR |
| 2024-03-21 | CTMX | Sell (S) | −5,268 | -$11.0K | EDGAR |
| 2024-01-19 | CTMX | Grant (A) | +25,000 | $0 | EDGAR |
| 2023-12-22 | CTMX | Sell (S) | −4,077 | -$5.6K | EDGAR |
| 2023-12-19 | CTMX | Exer (M) | +11,250 | $0 | EDGAR |
| 2023-09-22 | CTMX | Mixed | +9,514 | -$7.1K | EDGAR |
| 2023-03-20 | CTMX | Sell (S) | −2,037 | -$4.0K | EDGAR |
| 2023-02-06 | CTMX | Grant (A) | +25,000 | $0 | EDGAR |
| 2022-08-12 | CTMX | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).